Pharmaceuticals News and Research

RSS

Half of Britons at risk from heart disease

More than half the people tested in a national pharmacy initiative to identify the threat of high blood pressure were found to be at risk according to new research launched today at the British Pharmaceutical Conference.

27 Sep 2004

People with diabetes may soon be able to swap their tablets for creams and ointments

This news will come as a relief for type 2 diabetes patients who are routinely treated with oral hypoglycaemic drugs to lower their blood glucose levels. These can cause severe gastrointestinal side effects, such as nausea, vomiting and diarrhoea.

27 Sep 2004

Active ingredients of soya may help beat breast cancer

Researchers are investigating whether it is possible to turn the active ingredients of soya into a useful medicine that may help to beat breast cancer, the British Pharmaceutical Conference heard today.

27 Sep 2004

Half of sildenafil samples purchased on the internet were fake

Around half of the Viagra samples purchased on the Internet were counterfeit, according to researchers who are today announcing a new technique that detects counterfeit medicines at the British Pharmaceutical Conference.

27 Sep 2004

South African sales of MedMira rapid HIV tests begin

MedMira Inc., the international market leader in rapid flow- through diagnostic technology announced today that it has begun shipment of its MiraWell(TM) Rapid HIV Test to its distributor.

26 Sep 2004

Ranbaxy receives FDA approval to market Loratadine and Pseudoephedrine Sulfate extended release tablets

Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets

26 Sep 2004

Drug companies and FDA crack down on Canadian drug importation to protect profits

With an election on the horizon, and Canadian pharmacies proving to be as safe as U.S. counterparts, the Food and Drug Administration and big pharma are increasing efforts to prevent Canadian drug importation.

26 Sep 2004

Researchers reduce the toxicity of water-soluble buckyballs by a factor of more than ten million

Researchers at Rice University's Center for Biological and Environmental Nanotechnology (CBEN) have demonstrated a simple way to reduce the toxicity of water-soluble buckyballs by a factor of more than ten million.

26 Sep 2004

Drug shortages are having major negative effects on patient care and hospital costs

A study to be published in the October 1, 2004, issue of the American Journal of Health-System Pharmacy finds that ongoing drug shortages are having far-ranging, negative effects on patient care and hospital costs.

26 Sep 2004

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder

AstraZeneca has announced important new data at the 4th European Stanley Foundation Conference on Bipolar Disorder, which show Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder and is also well-tolerated in this difficult to treat patient population.

26 Sep 2004

Elan and Wyeth receive patents for Alzheimer's disease treatments

Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies’ joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer’s disease.

23 Sep 2004

Genes in poppy could hold the key to producing improved pain management pharmaceuticals

"The genes we found behaved differently in Norman compared to standard morphine producing poppies and were consistently associated with the blockage in morphine synthesis and with the accumulation of thebaine and oripavine," Dr Larkin says.

23 Sep 2004

PA Consulting sells drug delivery venture, Meridica, to Pfizer

Pfizer and PA Consulting Group have announced the signing of a transaction in which Pfizer will purchase the remaining 90% ownership of Meridica Limited

23 Sep 2004

GlaxoSmithKline has granted a voluntary licence to Cosmos Limited for the manufacture and sale of antiretrovirals

GlaxoSmithKline currently sells zidovudine (sold as Retrovir®), lamivudine (sold as Epivir®) and the combination of the two molecules (sold as Combivir®) across the region.

22 Sep 2004

University of Arizona spin-off investigates DNA damage to human skin

Niadyne, Inc., a Tucson-based spin-off biopharmaceutical company co-founded by two University of Arizona professors, has received a Small Business Innovation Research grant of nearly $750,000 to continue investigating the prevention of DNA damage to human skin

22 Sep 2004

Investigation into the potential for designing drug treatments based on a person’s genetic makeup

Most current drugs are not effective for 100 per cent of the population and some work in as few as 30 to 50 per cent of cases. Pharmacogenetics, the study of how genetic factors influence a person’s response to a drug, is seen as a way of making treatments as safe and effective as possible for every individual.

20 Sep 2004

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.

20 Sep 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

BBC focuses on the rise of complementary or alternative medicines

Broadcaster Anna Ford investigates why people are turning to CAM in a new six part BBC Radio Four series, The Other Medicine. Is there any evidence that CAM works, is it harmful and should the CAM industry, worth £1.6 billion a year, be made more available on the NHS?

20 Sep 2004

Pharmaceuticals News and Research

Half of Britons at risk from heart disease

People with diabetes may soon be able to swap their tablets for creams and ointments

Active ingredients of soya may help beat breast cancer

Half of sildenafil samples purchased on the internet were fake

South African sales of MedMira rapid HIV tests begin

Ranbaxy receives FDA approval to market Loratadine and Pseudoephedrine Sulfate extended release tablets

Drug companies and FDA crack down on Canadian drug importation to protect profits

Researchers reduce the toxicity of water-soluble buckyballs by a factor of more than ten million

Drug shortages are having major negative effects on patient care and hospital costs

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder

Elan and Wyeth receive patents for Alzheimer's disease treatments

Genes in poppy could hold the key to producing improved pain management pharmaceuticals

PA Consulting sells drug delivery venture, Meridica, to Pfizer

GlaxoSmithKline has granted a voluntary licence to Cosmos Limited for the manufacture and sale of antiretrovirals

University of Arizona spin-off investigates DNA damage to human skin

Investigation into the potential for designing drug treatments based on a person’s genetic makeup

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

BBC focuses on the rise of complementary or alternative medicines

Pittcon Highlights: Pharmaceutical & Biologic eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News